TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06999590: A Multicenter, Prospective, Randomized Controlled Modified Platform Trial Evaluating Several Cellular, Acellular, and Matrixlike Products (CAMPs) and Standard of Care Versus Matched Standard of Care Controls in the Manag

Sponsor: Tiger Biosciences, LLC. · Phase: PHASE4 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 500 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,499,200

Rescue Site Savings

+$5,604,160

Unlock Full NCT06999590 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06999590 Rescue Dossier →